Annual Cash & Cash Equivalents
$4.80 M
-$3.35 M-41.13%
30 June 2024
Summary:
NanoViricides annual cash & cash equivalents is currently $4.80 million, with the most recent change of -$3.35 million (-41.13%) on 30 June 2024. During the last 3 years, it has fallen by -$15.72 million (-76.62%). NNVC annual cash & cash equivalents is now -86.93% below its all-time high of $36.70 million, reached on 30 June 2014.NNVC Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$3.87 M
-$931.50 K-19.42%
01 September 2024
Summary:
NanoViricides quarterly cash and cash equivalents is currently $3.87 million, with the most recent change of -$931.50 thousand (-19.42%) on 01 September 2024. Over the past year, it has dropped by -$3.10 million (-44.53%). NNVC quarterly cash and cash equivalents is now -90.60% below its all-time high of $41.12 million, reached on 30 September 2014.NNVC Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NNVC Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -41.1% | -44.5% |
| 3 y3 years | -76.6% | -80.4% |
| 5 y5 years | +87.8% | +341.9% |
NNVC Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -76.6% | at low | -80.4% | +18.7% |
| 5 y | 5 years | -76.6% | +87.8% | -83.1% | +446.4% |
| alltime | all time | -86.9% | +487.7% | -90.6% | +654.7% |
NanoViricides Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $3.87 M(-19.4%) |
| June 2024 | $4.80 M(-41.1%) | $4.80 M(+47.3%) |
| Mar 2024 | - | $3.26 M(-37.9%) |
| Dec 2023 | - | $5.25 M(-24.7%) |
| Sept 2023 | - | $6.97 M(-14.5%) |
| June 2023 | $8.15 M(-42.1%) | $8.15 M(-15.6%) |
| Mar 2023 | - | $9.65 M(-15.7%) |
| Dec 2022 | - | $11.45 M(-11.4%) |
| Sept 2022 | - | $12.92 M(-8.2%) |
| June 2022 | $14.07 M(-31.4%) | $14.07 M(-9.7%) |
| Mar 2022 | - | $15.57 M(-10.2%) |
| Dec 2021 | - | $17.34 M(-12.0%) |
| Sept 2021 | - | $19.70 M(-4.0%) |
| June 2021 | $20.52 M(+49.7%) | $20.52 M(-10.4%) |
| Mar 2021 | - | $22.90 M(+24.5%) |
| Dec 2020 | - | $18.39 M(-15.6%) |
| Sept 2020 | - | $21.79 M(+59.0%) |
| June 2020 | $13.71 M(+436.5%) | $13.71 M(+124.5%) |
| Mar 2020 | - | $6.11 M(+762.8%) |
| Dec 2019 | - | $707.60 K(-19.1%) |
| Sept 2019 | - | $875.00 K(-65.8%) |
| June 2019 | $2.56 M(-63.9%) | $2.56 M(-39.7%) |
| Mar 2019 | - | $4.24 M(+8.5%) |
| Dec 2018 | - | $3.90 M(-35.8%) |
| Sept 2018 | - | $6.08 M(-14.1%) |
| June 2018 | $7.08 M(-53.1%) | $7.08 M(-33.3%) |
| Mar 2018 | - | $10.62 M(-11.9%) |
| Dec 2017 | - | $12.05 M(-10.8%) |
| Sept 2017 | - | $13.51 M(-10.5%) |
| June 2017 | $15.10 M(-37.5%) | $15.10 M(-6.5%) |
| Mar 2017 | - | $16.16 M(-16.3%) |
| Dec 2016 | - | $19.30 M(-11.9%) |
| Sept 2016 | - | $21.91 M(-9.3%) |
| June 2016 | $24.16 M(-23.2%) | $24.16 M(-5.6%) |
| Mar 2016 | - | $25.60 M(-9.4%) |
| Dec 2015 | - | $28.24 M(-4.2%) |
| Sept 2015 | - | $29.48 M(-6.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2015 | $31.47 M(-14.2%) | $31.47 M(-7.2%) |
| Mar 2015 | - | $33.92 M(-3.8%) |
| Dec 2014 | - | $35.26 M(-14.3%) |
| Sept 2014 | - | $41.12 M(+12.1%) |
| June 2014 | $36.70 M(+163.6%) | $36.70 M(+10.3%) |
| Mar 2014 | - | $33.27 M(+96.3%) |
| Dec 2013 | - | $16.95 M(-11.7%) |
| Sept 2013 | - | $19.20 M(+37.9%) |
| June 2013 | $13.92 M(-2.5%) | $13.92 M(-9.9%) |
| Mar 2013 | - | $15.46 M(+11.4%) |
| Dec 2012 | - | $13.88 M(+7.3%) |
| Sept 2012 | - | $12.93 M(-9.4%) |
| June 2012 | $14.28 M(+54.8%) | $14.28 M(+9.9%) |
| Mar 2012 | - | $12.98 M(+7.3%) |
| Dec 2011 | - | $12.10 M(+11.2%) |
| Sept 2011 | - | $10.88 M(+17.9%) |
| June 2011 | $9.22 M(+32.6%) | $9.22 M(+18.8%) |
| Mar 2011 | - | $7.76 M(-13.7%) |
| Dec 2010 | - | $8.99 M(+17.2%) |
| Sept 2010 | - | $7.68 M(+10.4%) |
| June 2010 | $6.96 M(+311.7%) | $6.96 M(+135.9%) |
| Mar 2010 | - | $2.95 M(-26.9%) |
| Dec 2009 | - | $4.03 M(-4.0%) |
| Sept 2009 | - | $4.20 M(+148.8%) |
| June 2009 | $1.69 M(+106.9%) | $1.69 M(+37.6%) |
| Mar 2009 | - | $1.23 M(-36.6%) |
| Dec 2008 | - | $1.94 M(-35.2%) |
| Sept 2008 | - | $2.99 M(+265.7%) |
| June 2008 | $816.40 K(-15.6%) | $816.40 K(-32.6%) |
| Mar 2008 | - | $1.21 M(-37.2%) |
| Dec 2007 | - | $1.93 M(-29.6%) |
| Sept 2007 | - | $2.74 M(+183.0%) |
| June 2007 | $967.80 K(-61.4%) | $967.80 K(+88.9%) |
| Mar 2007 | - | $512.30 K(-62.0%) |
| Dec 2006 | - | $1.35 M(-24.1%) |
| Sept 2006 | - | $1.78 M(-29.1%) |
| June 2006 | $2.51 M | $2.51 M |
FAQ
- What is NanoViricides annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for NanoViricides?
- What is NanoViricides annual cash & cash equivalents year-on-year change?
- What is NanoViricides quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for NanoViricides?
- What is NanoViricides quarterly cash and cash equivalents year-on-year change?
What is NanoViricides annual cash & cash equivalents?
The current annual cash & cash equivalents of NNVC is $4.80 M
What is the all time high annual cash & cash equivalents for NanoViricides?
NanoViricides all-time high annual cash & cash equivalents is $36.70 M
What is NanoViricides annual cash & cash equivalents year-on-year change?
Over the past year, NNVC annual cash & cash equivalents has changed by -$3.35 M (-41.13%)
What is NanoViricides quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NNVC is $3.87 M
What is the all time high quarterly cash and cash equivalents for NanoViricides?
NanoViricides all-time high quarterly cash and cash equivalents is $41.12 M
What is NanoViricides quarterly cash and cash equivalents year-on-year change?
Over the past year, NNVC quarterly cash and cash equivalents has changed by -$3.10 M (-44.53%)